Anaveon appoints Dr Gary Phillips as Chief Business Officer

 ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

— Dr Phillips brings 30 years of healthcare leadership experience in commercial operations, business strategy, business development and drug development functions —

Basel, July 13, 2022 – Anaveon, a clinical-stage immuno-oncology company, today announces the appointment of Dr Gary Phillips as Chief Business Officer with immediate effect. Dr Phillips has three decades of leadership experience in multiple roles across the healthcare industry, most recently serving as President & CEO of OrphoMed. In his role at Anaveon, Dr Phillips will serve on the executive committee and will shape and oversee Anaveon’s business and corporate development strategy.

“Gary has broad experience in leadership roles and long-standing relationships across the life sciences industry and I am delighted to welcome him to our executive committee,” said Dr Andreas Katopodis, Chief Executive Officer at Anaveon. “He joins us at an exciting time and his experience will be invaluable as we progress our lead program, ANV419, through development in multiple tumor types and expand our pipeline with novel late-preclinical drug candidates.”

“I am excited to join Anaveon at this time, with the unique characteristics of ANV419 pointing to its potential as a transformational therapy for patients with cancer, both as monotherapy and in combination with other therapies,” added Dr Gary Phillips. “I look forward to working with the experienced team and to shaping Anaveon’s business and corporate strategy.”

Dr Gary Phillips has three decades of experience across healthcare. He was President & CEO of OrphoMed from 2018 to 2022. Prior to OrphoMed, Dr Phillips was EVP & Chief Strategy Officer as well as President, Autoimmune & Rare Diseases at Mallinckrodt Pharmaceuticals. He was previously Head of Global Health & Healthcare at the World Economic Forum and has served in senior executive roles at Reckitt Benckiser Pharmaceuticals, Bausch & Lomb, Merck Serono, Novartis, and Wyeth. He earned a BA in Biochemistry summa cum laude from the University of Pennsylvania’s College of Arts & Sciences, an MBA from its Wharton School, and an MD Alpha Omega Alpha from its School of Medicine. Dr Phillips practiced as a U.S. Navy general medical officer. He currently serves as Chairman of the Board of Nanobiotix as well as a Director on the Boards of Aldeyra Therapeutics and Rheon Medical SA.

ENDS 

Enquiries

JW Communications
Julia Wilson
Tel: +44 (0)7818 430877
Email: julia.wilson@anaveon.com

About Anaveon

Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology. For further information please visit the Company’s website at: www.anaveon.com.

Latest News

29.05.2024
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

— ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential — Basel, 29 May 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug…
Read more
14.12.2023
Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of Cancer ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of Cancer

— ANV419 delivers high dose IL-2 to patients with a good safety and tolerability profile —
Basel, December 14, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced the publication of updated clinical data from the ongoing Phase I study of ANV419…
Read more
01.11.2023
Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors

— ANV600 is a potent, cis-signaling, IL-2Rβ/γ agonist which efficiently expands intratumoral stem-like CD8+ T cells —
Basel, November 1, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the 38th Annual Meeting…
Read more
Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com
Our website uses cookies to provide you with the best online experience. By using our website, you accept the use of cookies in accordance with our Privacy Policy.
Accept